LeadArtis awarded with a RIS3 grant from the Comunidad Autónoma de Madrid in recognition of its highly innovative R&D activity.

08-03-2016

The Ministry of Economy and Finance of the Community of Madrid (MEFCAM), following the recommendations of the European Union, has established the regional strategy for research and innovation for smart specialization of the Community of Madrid framework (hereinafter RIS3) to support the development of highly specialized innovating companies with a requirement of permanent competitiveness. Consequently, the RIS3 grants are meant to increase innovative activity within the industry promoting innovative projects. As a result of an extremely competitive assessment of hundreds of business projects and companies, LeadArtis has been awarded with a substantial endowment that will be used to advancing its immune-oncology therapeutics pipeline.

LeadArtis is a preclinical stage health biotechnology company located in Madrid (www.leadartis.com) focused on producing multivalent immune stimulating antibodies through its unique Trimerbody® technology. The Trimerbodies exhibit excellent antigen binding capacity, functionality and stability.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes
11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...